Vertex appoints Terrence Kearney to board
This article was originally published in Scrip
Vertex Pharmaceuticals has elected Terrence Kearney to its board of directors, bringing the number of Vertex board members to nine. Mr Kearney most recently served as chief operating officer for Hospira. Prior to Hospira, he spent over 20 years at Abbott Laboratories in various financial management roles.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.